Oxavar-3

Oxavar (Anavar Oxandrolone)

$92.00

Product Description

Manufacturer: Unigen Life Sciences

Category: Oral Steroids

Substance: Anavar (Oxandrolone)

Package: 10mg x 50 tablets

Oxandrolone is a mild, low androgen 17-alpha alkylated anabolic steroid with very low toxicity. It promotes protein anabolism and has a low incidence of adverse reactions. Oxandrolone is primarily used to promote strength, muscle hardness and quality physique improvement. In the International Journal of Obesity, (1995; 19: 614-624), it was shown that Oxandralone enhanced bodyfat reduction significantly in both the abdominal and visceral stores. Oxandrolone will not aromatize, and therefore the anabolic effect of this compound can actually promote linear growth.

CLINICAL PHARMACOLOGY:

Anabolic steroids are synthetic derivatives of testosterone, having actions similar to the endogenous male sex hormone testosterone. There is not a complete dissociation of the anabolic versus androgen action.

Anabolic steroids may suppress gonadotrophic function of the pituitary and may also have a direct effect on the testes. During exogenous administration of anabolic steroids and androgens, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH). With large doses, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH).

The actions of anabolic steroids are similar to male sex hormones. Anabolic steroids may cause growth disturbances and induce premature sexual development if administered to young children.

Anabolic steroid hormones may increase low-density lipoproteins (LDL) and decrease high density lipoproteins (HDL). Lipids levels generally return to normal upon discontinuation of treatment.

In a single dose pharmacokinetic study of oxandrolone in geriatric subjects, the average elimination half-life was 13.3 hours. In a similar pharmacokinetic study in younger subjects, the average elimination half-life was 10.4 hours. No significant differences between geriatric and younger test subjects were found for time to peak absorption, peak plasma concentration, or AUC after a single dose. The correlation between plasma level and therapeutic effect has not yet been established.